The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Guan Yu
Employment - Bristol Myers Squibb Foundation (I)
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation (I)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Shannon L. Puhalla
Consulting or Advisory Role - Abbvie; AstraZeneca; Celldex; Eisai; Pfizer; Puma Biotechnology
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Covance/Bayer (Inst); Incyte (Inst); Lilly (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
 
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Patents, Royalties, Other Intellectual Property - Patent No PCT/US2022/021720, "Small molecules and their use as MALT1 inhibitors"
 
Ibrahim Halil Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline; Guardant Health; Seagen
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Foundation Medicine; Illumina; Lilly; Pfizer; Regeneron; Seagen; STRATA Oncology
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Philip A. Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Theodore S. Hong
Stock and Other Ownership Interests - PanTher Therapeutics
Consulting or Advisory Role - Boston Scientific; Merck; NextCure; Novocure; Syndax; Synthetic Biologics
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
 
Yesenia Rojas-Khalil
No Relationships to Disclose
 
Jonathan M. Loree
Consulting or Advisory Role - Advanced Accelerator Applications; AMGEN; Bayer; Ipsen; Pfizer; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Ipsen (Inst)
 
Norman Wolmark
Travel, Accommodations, Expenses - Komen Award, SABCS, 2022
 
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics
 
Thomas J. George
Consulting or Advisory Role - Avammune Therapeutics; BillionToOne; KAHR Medical; Nihon Medi-Physics; Seagen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BillionToOne (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst)
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Amgen (Inst)
Research Funding - Genentech (Inst)